Conference Coverage

Lessons learned from the PCSK9 inhibitor trials
LOS ANGELES – The higher your risk, the greater your benefit from therapeutic intervention.
LOS ANGELES – The higher your risk, the greater your benefit from therapeutic intervention.
Patients with Tourette syndrome or chronic tic disorder have a higher risk for metabolic and cardiovascular health problems, a population-based...
LOS ANGELES – The combination of heart failure and diabetes is particularly lethal.
LOS ANGELES – Hepatic insulin clearance is significantly lower in African Americans, compared with European Americans, a difference that may...
LOS ANGELES – Direct evidence of a link between obesity in youth and adult cardiovascular disease is beginning to emerge.
NASHVILLE, TENN. – The real-world study saw more adverse events – but no attrition from side effects.
NASHVILLE – The most effective apps took advantage of gamification and other uniquely digital features.
NASHVILLE – Teetotalers had the best luck maintaining weight loss, but the differences were small.
Complete results are expected by the end of 2019.
Cluster of conditions “is now the main driver of the global chronic disease epidemic and its health burden,” expert says.
BERLIN – An increase in lower extremity amputations was seen among patients with type 2 diabetes mellitus who were treated with diuretics.
“This study provides further support for the notion that depression with comorbid anxiety symptoms might represent a group...
BERLIN – In the first year after the initiation of continuous glucose monitoring, hypoglycemia episodes needing external help were significantly...
BERLIN – Severe hypoglycemia was reversed successfully in all patients with type 1 diabetes mellitus given nasal glucagon.
Mortality declined dramatically in patients with type 2 diabetes mellitus who took the medication over an average of 3 years.
BERLIN – LeucoPatch, which contains patients’ own platelets, fibrin, and leukocytes, enabled more diabetic ulcers to heal versus standard care.
The appetite-suppressant drug lorcaserin has benefits ranging from lower rates of incident type 2 diabetes mellitus and improved glycemic control...
BERLIN – The ADA and EASD have issued their 2018 Consensus Report on the management of hyperglycemia in type 2 diabetes.
BERLIN – HbA1c and body weight were significantly lowered, compared with placebo and dulaglutide, by the dual GIP/GLP-1 receptor agonist LY3298176...